INTRODUCTION
Use of a partially mismatched-related donor is an option for patients who require Allo-SCT but do not have a matched sibling or unrelated donor. It might be even a first choice, especially in advanced hematological malignancies, because of the presumed stronger graft versus tumor effect related to the partial HLA identity. [1] [2] [3] [4] Haplo-identical Allo-SCT (haplo-SCT) recipients are at high risk for invasive fungal infection (IFI) involving both Candida and Aspergillus species. 5, 6 The risk is associated with the degree and duration of neutropenia, the disruption of protective skin and mucosal surface barriers, the GVHD and the use of corticosteroids. 7, 8 As IFIs are life threatening and their early diagnosis difficult to establish, primary antifungal prophylaxis is highly recommended in current guidelines (ECIL, IDSA, ASBMT). In case of high-risk transplantation, such as haplo-SCT, treatments with activity against both Candida and Aspergillus species have an advantage over those with activity against Candida alone. Safety profile, potential for drug interactions, administration route and frequency, as well as cost and emerging resistance, are also important parameters of choice.
Echinocandins are a novel class of antifungal agents active against Candida and Aspergillus species, as well as Pneumocystis jiroveci. 9, 10 They inhibit the biosynthesis of b-1,3-glucan, an essential component of the fungal cell wall. [11] [12] [13] Their antifungal effect on Aspergillus species poises these agents for optimal prophylactic effect early during hyphal growth. 12, 14 As b-1,3-glucan is not present in mammalian cells, they have little human toxicity attributed to their mechanism of action. Micafungin, one of them, is metabolized through the O-methyl transferase pathway, thus minimizing the potential for drug interactions in complicated patients with neutropenia. Unlike fluconazole, micafungin does not interact with drugs whose metabolism is mediated via the cytochrome P450. 15 Specifically, drug interaction studies demonstrated that no dose adjustment is required during its coadministration with immunosuppressant agents, 16 and also that no dose adjustment is necessary in patients with renal impairment. Mycamine has been granted marketing authorization for prophylaxis of Candida infection in patients undergoing hematopoietic SCT or being expected to have neutropenia for at least 10 days. It was shown to have a significantly greater efficacy than fluconazole in preventing proven, probable or suspected IFIs in patients receiving either Allo-or Auto-SCT. [17] [18] [19] One of the major concerns about the use of fluconazole is its lack of activity against Aspergillus species and some non albicans Candida species. 9, 11 The aim of this study was to confirm the efficacy and safety of micafungin for prophylaxis of IFI in patients undergoing haplo-SCT in current practice.
PATIENTS AND METHODS
This was an observational single-centre trial conducted at the Transplant and Cell Therapy Unit of Paoli-Calmettes Institute of Marseille (France). Eligible patients were those who required partially mismatched-related donor transplantation for hematological malignancy. Patients also had to be free of deeply invasive fungal disease at the time of enrollment. They should not have received systemic antifungal therapy within 72 h before administration of the first dose of micafungin. They had to be free of liver disease, as defined by serum aminotransferase levels o5 times the upper limit of normal or by bilirubin levels o2.5 times the upper limit of normal. Study procedures were reviewed and approved by the institutional review board at our center before patient enrollment start. Written informed consent was obtained from each patient before treatment. Patients were not included if they had history of anaphylaxis attributable to echinocandin compounds. In our cohort, only two patients had a history of possible aspergillosis before transplant treated by voriconazole and were off therapy and considered in CR from IFI at the time of haplo-SCT.
Infection prophylaxis and supportive care
Supportive care was identical during the whole study period. P. jiroveci pneumonia prophylaxis consisted of trimethoprim-sulfamethoxazole (10 mg/kg/day trimethoprim) administered twice weekly in all patients with satisfactory engraftment. Patients received daily oral amoxicillin (500 mg Â 3/day) prophylaxis against encapsulated bacteria. Prophylaxis against HSV included oral valacyclovir (500 mg Â 2/day) during the treatment with micafungin.
Interventions
Micafungin was administered once daily as a 1-h infusion (50 mg/kg/day) during the neutropenic (that is, pre-engraftment) phase of haplo-SCT. It was prescribed from the beginning of the transplant-related conditioning regimen until the hospital discharge. After the hospital discharge, 18 patients (69%) received fluconazole 400 mg/day until day 90 after haplo-SCT in case of no GVHD or posaconazole (two patients) if they had presented an acute GVHD. It was discontinued earlier in case of proven, probable, or suspected IFI, or unacceptable drug toxicity, or death.
Patients were monitored after haplo-SCT for galactomannan antigenemia at least once per week, and a computed tomography scan was performed in the case of persistent fever for at least 5 days after broad-spectrum empirical antibacterial therapy. Routine controls (for example, detection of galactomannan antigenemia and computed tomography scan) were performed systematically after 1 and 2 months and on day 100 after haplo-SCT.
Outcomes
Proven infection was defined as biopsy-proven invasive or disseminated infection. Sinus or pulmonary infection with Aspergillus, Fusarium or Zygomycetes organisms also was considered to be proven, if results of cultures of specimens obtained from the respiratory tract were positive in conjunction with compatible diagnostic imaging findings. Patients were deemed to have probable pulmonary aspergillosis, if lower respiratory tract diagnostic studies revealed fungal elements in conjunction with compatible clinical and radiographic findings. These criteria for proven and probable infection are consistent with those for IFI described by the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, National Institute of Allergy and Infectious Diseases Mycoses Study Group. Fungal infection was defined as suspected, if fever (temperature, 438 1C) persisted for 496 h during the neutropenic phase, despite broad-spectrum antibacterial therapy, and led to the initiation of empirical antifungal therapy. 8 The primary end point was treatment success, defined as the absence of proven, probable, or suspected systemic fungal infection through the end of prophylaxis therapy and as the absence of a proven or probable systemic fungal infection through the end of the 12-week post-treatment period (European Organization for Research and Treatment of Cancer criteria).
The use of systemic antifungal agents for treatment of suspected fungal infections, the frequency of proven or probable fungal infections throughout the post-treatment period and the pathogen-based frequency of proven infections were analyzed as secondary efficacy variables. Other secondary outcome measurements included the frequency of superficial fungal infection, the frequency of fungal colonization, the time to treatment failure, the time to suspected fungal infection and mortality.
Safety analyses included adverse events, results of clinical laboratory tests, and vital signs. Laboratory-based hematological and serum chemistry analyses and fungal surveillance cultures were performed at the study sites at baseline, at least once weekly while study drug was administered, and on the final day of therapy.
In accordance with the standards of good clinical practice, adverse events that occurred up to 72 h after the administration of the final dose of study drug were captured on report forms. All patients are considered, as high-risk allogeneic transplant criteria included acute leukemia in relapse or in CR for at least the third time, Hodgkin lymphoma or non-Hodgkin lymphoma in relapse or greater than or equal to the second complete or PR, myelodysplastic syndrome, myeloproliferative syndrome, and multiple myeloma in relapse after three lines of chemotherapy and who received at least one Auto-SCT.
RESULTS
Between September 2010 and July 2012, 26 patients from our department were enrolled. Half of them had previously undergone at least one Auto-SCT and eight patients (31%) one Allo-SCT. Patients received a median of seven lines (2-8) of chemotherapy before haplo-SCT. Twenty-four patients (92%) received a reduced intensity conditioning regimen (RIC). Of those 21 patients (80%), the RIC regimen consisted of fludarabine (30 mg/m 2 i.v.) on days À 6 to À 2, CY (14.5 mg/kg i.v.) from days À 6 to À 5 and TBI (200 cGy) on day À 1, or fludarabine, BU and CY based in 2 patients (8%) or other (4%) while two patients (8%) received a myeloablative conditioning regimen with thiotepa. For GVHD prophylaxis patients with RIC received post-transplant CY (50 mg/ kg i.v.) on days þ 3 and þ 4 with Mesna. One day later, all patients started with CsA (ciclosporin A) (3 mg/kg/day), mycophenolate mofetil (15 mg/kg/day) and filgrastim (G-CSF) (5 mg/kg/day) until neutrophil recovery. Mycophenolate mofetil was stopped at day þ 35 and CsA was given until day þ 180 in the absence of GVHD. The patients and transplant details are shown in the Table 1 . Three patients (14%) experienced a graft failure, four patients (15%) presented an acute GVHD grade II and two patients (8%) presented an extensive chronic GVHD.
Patients received a median of 29 infusions (range, 15-85) of micafungin. Neither Candida nor Aspergillus infection was documented 3 and 6 months after transplantation. None of our patients presented a positive galactomannan antigenemia 40.5 ( Figure 1 ). Seven (32%) had a CMV reactivation. No therapy failure was observed requiring the use of empirical systemic antifungal agents. A total of 14 patients (58%) presented a documented bacterial infection, 7 patients with Gram-positive cocci and 7 patients with Gram-negative rods. All the 14 analyzable pathogenic microorganisms are classified in the Table 2 by descending order of frequency. At last follow-up, there are 20 patients (77%) who are alive, with a median follow-up of 11 months (3-23). The OS and the PFS at 1 year was 79% (95% CI: 63-95) (Figures 2  and 3) . The primary cause of death was relapse of the original disease in four patients (15%) and graft failure in two patients. The TRM at 1 year was 9% (95% CI: 0-21), whereas the relapse or progression rate at 1 year was 15% (95% CI: 0-24) (Figure 4 ).
Adverse events
No infusion-related adverse event was observed. There was no treatment discontinuation because of drug-related adverse event. Micafungin was not associated with any hepatotoxicity ( Figure 5 ). Of two patients with an elevated bilirubin level, one had an early progressive Hodgkin disease and the second one developed progressive myelofibrosis and secondary hemochromatosis. One patient only (5%) discontinued the treatment and was transferred to the intensive care unit because of early disease progression. There were no significant differences in aminotransferase levels in patients receiving CsA immunosuppressive therapy concomitantly with micafungin. Mortality A total of six patients (23%) died during the study because of disease progression (four cases) and graft failure (two cases). The median time to death was 77 days. None of the deaths was related to the study drug and none was associated with any fungal infection.
DISCUSSION
Haplo-SCT is a curative alternative option for patients without an otherwise suitable stem cell donor. However, haplo-SCT has several limitations including higher graft failure rate, delayed immune reconstitution after transplantation with high rates of lifethreatening infections and severe acute and chronic GVHD. 20, 21 A delayed hematologic and immunologic reconstitution is common after this therapeutic strategy, and impaired immune function after haplo-SCT with subsequent infections is a major cause of deaths in these patients. 22, 23 Fluconazole has been routinely used in our center and several other institutions for many years and has become the standard treatment for the prophylaxis of IFI, because of its excellent antifungal effects in patients who have undergone Allo-SCT. However, it does not protect patients against invasive aspergillosis, which is an important concern in this high-risk population. Moreover, the recent emergence of resistance to fluconazole has highlighted the need for more effective and alternative drugs. [24] [25] [26] [27] [28] We therefore hypothesized that micafungin would be an alternative to fluconazole as antifungal prophylaxis, with broader-spectrum activity against invasive aspergillosis during neutropenia. We conducted this observational study to evaluate the safety and efficacy of micafungin for prophylaxis of IFI in a high-risk homogeneous population of patients undergoing haplo-SCT, who received a median of seven lines of chemotherapy. As far as we know, this is the first study reporting on the role of micafungin in such patients.
In a prospective, double-blind, randomized, phase III trial, micafungin has been shown to be more efficacious than fluconazole in preventing IFI in a population of 882 patients at high risk of developing a systemic fungal infection. 17 The overall success rate was significantly higher for patients in the micafungin arm (80%) compared with 73.5% in the fluconazole arm (P ¼ 0.03). Micafungin was also more effective in reducing the need for empirical antifungal therapy (P ¼ 0.024). This study was conducted in a very heterogeneous population, including pediatric and adult patients receiving Auto-or Allo-SCT or cord blood SCT. This study, as well as the one conducted by Goodman et al. was designed to assess the efficacy of antifungal therapy during neutropenia. Unlike our study, none was designed to address prophylaxis during the period following engraftment. 17, 25 In line with preclinical and previous clinical studies, our trial confirmed that micafungin administered to this specific population of high-risk neutropenic patients undergoing haplo-SCT was able to prevent both suspected and proven IFI. The overall success rate was significant, as we did not document any case of proven or probable IFI, not only during the neutropenic phase but also 3 and 6 months after transplantation. None of our patients presented a positive galactomannan antigenemia 40.5. Interestingly, no therapy failure was observed in our patients requiring the use of any empirical systemic antifungal agents.
Our results also confirmed that micafungin therapy is safe, as we did not observe any infusion-related adverse events in all 26 patients. None of our patients were withdrawn from the study Figure 1 . Galactomannan antigenemia values after haplo-SCT. The high value (7.37) observed at W2 for patient 9 was probably a false positive. Controls performed 3 and 7 days after were normal (0.09 and 0.07, respectively). Efficacy and safety of micafungin J El-Cheikh et al because of an adverse event. Only one patient (4%) discontinued the treatment because of early disease progression. Moreover, in our study, micafungin was not associated with any hepatotoxicity (Figure 1 ).
Conditioning regimen
In conclusion, this is the first study showing that the administration of micafungin at a daily dose of 50 mg i.v. is efficacious in preventing IFI in the high-risk population of patients undergoing haplo-SCT with a good safety and tolerability profile. The small sample size and the study design (not a randomized prospective trial) prevent us from drawing any significant conclusions or formulating future directions for the use of micafungin in prophylaxis after haplo-SCT. However, our data provide support for a further prospective and comparative efficacy study, to define the role of micafungin in prophylaxis after haplo-SCT. Figure 5 . Bilirubinemia values after haplo-SCT. High bilirubinemia values observed for patients 6, 14 and 20 were due to the progression of their haematological disease. Patient 20 had an early progression of an Hodgkim's Disease. He was transferred to intensive care unit because of multiorgan deficiency and died.
Efficacy and safety of micafungin J El-Cheikh et al
